Positive News Sentiment NASDAQ:ALDX Aldeyra Therapeutics - ALDX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. $9.03 -0.03 (-0.33%) (As of 03/24/2023 08:50 PM ET) Add Compare Share Share Today's Range$8.65▼$9.1250-Day Range$5.77▼$9.0652-Week Range$2.36▼$9.20Volume1.51 million shsAverage Volume490,537 shsMarket Capitalization$528.98 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aldeyra Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside127.0% Upside$20.50 Price TargetShort InterestHealthy3.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.35) to ($1.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector378th out of 995 stocksPharmaceutical Preparations Industry171st out of 482 stocks 3.5 Analyst's Opinion Consensus RatingAldeyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.50, Aldeyra Therapeutics has a forecasted upside of 127.0% from its current price of $9.03.Amount of Analyst CoverageAldeyra Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.56% of the float of Aldeyra Therapeutics has been sold short.Short Interest Ratio / Days to CoverAldeyra Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Aldeyra Therapeutics has recently decreased by 9.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAldeyra Therapeutics does not currently pay a dividend.Dividend GrowthAldeyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALDX. Previous Next 3.8 News and Social Media Coverage News SentimentAldeyra Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aldeyra Therapeutics this week, compared to 1 article on an average week.Search Interest34 people have searched for ALDX on MarketBeat in the last 30 days. This is an increase of 31% compared to the previous 30 days.MarketBeat Follows7 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of Aldeyra Therapeutics is held by insiders.Percentage Held by Institutions63.11% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aldeyra Therapeutics are expected to decrease in the coming year, from ($1.35) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aldeyra Therapeutics is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aldeyra Therapeutics is -8.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAldeyra Therapeutics has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aldeyra Therapeutics (NASDAQ:ALDX) StockAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Read More Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Stock News HeadlinesMarch 18, 2023 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Now Covered by StockNews.comMarch 11, 2023 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Q4 2022 Earnings Call TranscriptMarch 27, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 10, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Aldeyra Therapeutics (ALDX)March 10, 2023 | finance.yahoo.comQ4 2022 Aldeyra Therapeutics Inc Earnings CallMarch 9, 2023 | msn.comAldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10March 9, 2023 | finance.yahoo.comAldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate HighlightsMarch 8, 2023 | msn.comAldeyra Therapeutics Q4 2022 Earnings PreviewMarch 27, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 8, 2023 | msn.comEarnings Outlook For Aldeyra TherapeuticsMarch 3, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)March 2, 2023 | marketwatch.comAldeyra Gets FDA Priority Review for ADX-2191 in Rare Retinal Cancer >ALDXMarch 2, 2023 | finance.yahoo.comFDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal LymphomaMarch 1, 2023 | finance.yahoo.comAldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate HighlightsFebruary 28, 2023 | finance.yahoo.comAldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye DiseaseFebruary 23, 2023 | finance.yahoo.comAldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic AtrophyFebruary 22, 2023 | finance.yahoo.comOwning 40% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),February 16, 2023 | finance.yahoo.comAldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease TrialsFebruary 9, 2023 | finance.yahoo.comAldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma ConferenceFebruary 7, 2023 | finance.yahoo.comAldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye DiseaseJanuary 12, 2023 | finance.yahoo.comInsiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profitDecember 21, 2022 | msn.comAldeyra files for FDA approval of ADX‑2191 for rare eye cancerDecember 21, 2022 | markets.businessinsider.comAldeyra Therapeutics Submits NDA For ADX-2191December 21, 2022 | finance.yahoo.comAldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol IntoxicationDecember 21, 2022 | finance.yahoo.comAldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal LymphomaDecember 14, 2022 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Masimo (MASI), Aldeyra Therapeutics (ALDX)December 13, 2022 | finance.yahoo.comAldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALDX Company Calendar Last Earnings10/27/2021Today3/27/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALDX CUSIPN/A CIK1341235 Webwww.ampliphibio.com Phone781-761-4904Fax781-270-0630Employees15Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.50 High Stock Price Forecast$28.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+99.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.60% Return on Assets-31.22% Debt Debt-to-Equity Ratio0.10 Current Ratio11.78 Quick Ratio11.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book3.50Miscellaneous Outstanding Shares58,580,000Free Float54,476,000Market Cap$528.98 million OptionableOptionable Beta1.07 Key ExecutivesTodd C. Brady (Age 48)M.D., Ph.D., Chief Executive Officer and Director Joshua Reed (Age 47)Chief Financial Officer David McMullin (Age 45)Chief Commercial Officer James A. Gow (Age 53)M.D., Senior Vice President of Clinical Development Stephen G. Machatha (Age 43)Ph.D., Senior Vice President, Technical Operation Key CompetitorsEdgewise TherapeuticsNASDAQ:EWTXMacroGenicsNASDAQ:MGNXBiomea FusionNASDAQ:BMEABicycle TherapeuticsNASDAQ:BCYCNurix TherapeuticsNASDAQ:NRIXView All CompetitorsInsiders & InstitutionsParallax Volatility Advisers L.P.Sold 38,000 shares on 2/27/2023Ownership: 0.000%NatixisBought 44,258 shares on 2/24/2023Ownership: 0.076%Morgan StanleyBought 12,607 shares on 2/15/2023Ownership: 0.538%Alps Advisors Inc.Bought 7,943 shares on 2/15/2023Ownership: 0.068%Boothbay Fund Management LLCBought 13,525 shares on 2/15/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions ALDX Stock - Frequently Asked Questions Should I buy or sell Aldeyra Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALDX shares. View ALDX analyst ratings or view top-rated stocks. What is Aldeyra Therapeutics' stock price forecast for 2023? 3 brokerages have issued twelve-month price targets for Aldeyra Therapeutics' shares. Their ALDX share price forecasts range from $11.00 to $28.00. On average, they predict the company's share price to reach $20.50 in the next twelve months. This suggests a possible upside of 127.0% from the stock's current price. View analysts price targets for ALDX or view top-rated stocks among Wall Street analysts. How have ALDX shares performed in 2023? Aldeyra Therapeutics' stock was trading at $6.96 at the beginning of 2023. Since then, ALDX stock has increased by 29.7% and is now trading at $9.03. View the best growth stocks for 2023 here. When is Aldeyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our ALDX earnings forecast. How were Aldeyra Therapeutics' earnings last quarter? Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by $0.01. During the same period in the previous year, the company posted ($0.23) EPS. What ETFs hold Aldeyra Therapeutics' stock? ETFs with the largest weight of Aldeyra Therapeutics (NASDAQ:ALDX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS) and ALPS Medical Breakthroughs ETF (SBIO), What other stocks do shareholders of Aldeyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI). What is Aldeyra Therapeutics' stock symbol? Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX." Who are Aldeyra Therapeutics' major shareholders? Aldeyra Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Eagle Asset Management Inc. (3.03%), Verition Fund Management LLC (2.66%), Dimensional Fund Advisors LP (1.52%), Millennium Management LLC (1.45%), Geode Capital Management LLC (0.80%) and Two Sigma Investments LP (0.77%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady. View institutional ownership trends. How do I buy shares of Aldeyra Therapeutics? Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aldeyra Therapeutics' stock price today? One share of ALDX stock can currently be purchased for approximately $9.03. How much money does Aldeyra Therapeutics make? Aldeyra Therapeutics (NASDAQ:ALDX) has a market capitalization of $528.98 million. The biotechnology company earns $-62,030,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. How can I contact Aldeyra Therapeutics? Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The official website for the company is www.ampliphibio.com. The biotechnology company can be reached via phone at 781-761-4904, via email at ir@ampliphibio.com, or via fax at 781-270-0630. This page (NASDAQ:ALDX) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.